GlassScriptPhysician profile
Carol M Antequera
NPI 1063710549
$97,670.02
in general payments reported to CMS, 2019-2025
26 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,643 · 2022: $18K · 2023: $22K · 2024: $36K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Travel and Lodging: $14K · Consulting Fee: $14K · Food and Beverage: $7,045 · Honoraria: $4,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,831.33 |
| Travel and Lodging | $13,890.71 |
| Consulting Fee | $13,781.25 |
| Food and Beverage | $7,044.75 |
| Honoraria | $4,612.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $25,485.39 | 2021-2025 | Gimoti |
| Regeneron Healthcare Solutions, INC. | $25,204.38 | 2022-2025 | Dupixent |
| Genzyme Corporation | $19,016.94 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $8,845.00 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Ardelyx, INC. | $6,538.26 | 2022-2025 | Ibsrela |
| Abbvie INC. | $3,745.47 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $3,636.18 | 2023-2024 | Voquezna, Voquezna Dual Pak, Voquezna Triple Pak |
| Regeneron Pharmaceuticals, INC. | $1,249.31 | 2022-2025 | Dupixent |
| Novo Nordisk INC | $1,182.41 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $672.39 | 2021-2024 | |
| Mahana Therapeutics, INC. | $595.00 | 2022 | |
| Laborie Medical Technologies Corp. | $317.98 | 2022-2023 | |
| Gilead Sciences, INC. | $188.45 | 2024-2025 | |
| Orphalan INC | $159.00 | 2023-2024 | Cuvrior |
| Neurocrine Biosciences, INC. | $116.63 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.92 | 2023 | |
| Ironwood Pharmaceuticals, INC | $83.14 | 2025 | |
| Aimmune Therapeutics, INC. | $79.78 | 2025 | Zenpep |
| Qol Medical, LLC | $79.11 | 2022-2024 | Sucraid |
| Exact Sciences Corporation | $78.95 | 2025 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $73.96 | 2023-2024 | Rebyota |
| Axonics, INC. | $65.99 | 2021-2024 | Axonics |
| Dynavax Technologies Corporation | $65.73 | 2021-2023 | Heplisav-B |
| Mallinckrodt Hospital Products INC. | $30.75 | 2025 | Terlivaz |
| Janssen Biotech, INC. | $28.02 | 2025 | Tremfya |
| Lilly USA, LLC | $20.88 | 2025 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Antequera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.